Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 4/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PPID | Q08752 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16388795 | 0.86 | ALDH1A1 (0.58) | ANPEPCTSKSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL17789283 | 0.83 | ANPEP (0.52) | ANPEPCTSKSMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL16388799 | 0.77 | TAS1R3 (0.41) | CTSKALDH1A1PSMB5NPC1KMT2A | |
| SCHEMBL8842988 | 0.75 | ANPEP (0.56) | ANPEPCTSKHPGD | |
| SCHEMBL17083898 | 0.75 | MEN1 (0.65) | ANPEPALDH1A1MEN1KMT2A | |
| SCHEMBL10098394 | 0.75 | SCN9A (0.52) | SMN1; SMN2 | |
| SCHEMBL1792750 | 0.74 | PSMB5 (0.54) | ANPEPCTSKALDH1A1PSMB5MEN1 | |
| SCHEMBL1792753 | 0.74 | PSMB5 (0.54) | ANPEPCTSKALDH1A1PSMB5MEN1 | |
| SCHEMBL3451593 | 0.73 | PSMB5 (0.57) | ANPEPCTSKALDH1A1LMNAPSMB5 | |
| SCHEMBL3451636 | 0.73 | PSMB5 (0.57) | ANPEPCTSKALDH1A1LMNAPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152621-A1 | ARYL LACTAM KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| WO-2015006100-A1 | ARYL AMIDE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152621-A1 | ARYL LACTAM KINASE INHIBITORS | AAK1, ADCK1, ANKK1 | ANPEP 1763/4885CTSK 1026/4885SMN1; SMN2 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.